SUNNYVALE, Calif. – June 4, 2019 – Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced key data from the SVS TCAR Surveillance Project and ROADSTER-2 study will be presented at the upcoming Society for Vascular Surgery 2019 Vascular Annual Meeting (VAM), June 12-15 at the Gaylord National Resort & Convention Center in National Harbor, Maryland.
Data from the Society for Vascular Surgery’s TCAR Surveillance Project, launched in 2016 to obtain real-world comparative outcomes of TCAR and other carotid artery treatments from centers participating in the Vascular Quality Initiative (VQI), will be featured in podium and poster presentations, including:
• “Age and Outcomes After TransCarotid Artery Revascularization (TCAR), Transfemoral Carotid Artery Stenting (TF-CAS) and Carotid Endarterectomy (CEA)” (VESS14) will be presented by Dr. Hanaa Dakour Aridi of Johns Hopkins University School of Medicine during VESS Paper Session 1 on Wednesday, June 12 at 10:45 a.m. ET in Maryland D.
• “Outcomes of TransCarotid Artery Revascularization (TCAR) versus Carotid Endarterectomy (CEA) in the TCAR Surveillance Project” (SSO1) will be presented by Dr. Mahmoud Malas of the University of California, San Diego School of Medicine on Thursday, June 13 at 8:30 a.m. ET in Potomac A/B.
Read More: https://www.vasculardiseasemanagement.com/content/silk-road-medical-announces-key-tcar-presentations-society-vascular-surgery-2019-vascular
Silk Road Medical Announces Key TCAR Presentations at the Society for Vascular Surgery 2019 Vascular Annual Meeting
For diabetic workers, access to a refrigerator and insulin breaks are not a workplace perk. They are potentially a matter of life and death.
Gary Sunderland was recovering from a heart procedure at New Hanover Regional Medical Center when a physician assistant stopped by to assess him. Using a stethoscope, the physician assistant listened to the carotid artery in his neck.
Stealthy catheter developer Route 92 Medical, which is developing a catheter to treat stroke, last week said it raised nearly $13 million in an equity round.
SUNNYVALE, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2019.
Outset Medical Announced a KidneyX Award Winner by U.S. Department of Health and Human Services and the American Society of Nephrology
Company’s Research Initiative Recognized as Novel, Innovative Approach to Deliver More Personalized Dialysis Treatment
Via: The Times-News
The Centers for Disease Control and Prevention reports that nearly 800,000 people in the United States have suffered strokes. Stroke Awareness Month, which occurs in May, is quickly approaching, which makes this a good time to discuss the medical advances in this area. Thankfully, the medical field is rapidly advancing, and new techniques and procedures are created every year. Transcarotid artery revascularization (TCAR) is one such procedure that can change the lives of patients at risk for stroke.
Shares of Silk Road Medical (SILK) popped more than 80% on Thursday with an initial public offering that drew heavy interest from investors. The Silk Road Medical IPO raised $120 million.
SUNNYVALE, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq:SILK) (“Silk Road Medical”) today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $20.00 per share. All of the shares of common stock are being offered by Silk Road Medical. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Silk Road Medical’s common stock is expected to begin trading on The Nasdaq Global Market on April 4, 2019, under the ticker symbol “SILK”. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Silk Road Medical, are expected to be approximately $120 million. Silk Road Medical will not receive any proceeds from the sale of shares of common stock by the selling stockholders if the underwriters exercise their option to purchase additional shares. The offering is expected to close on April 8, 2019, subject to the satisfaction of customary closing conditions.
Medical device company Silk Road Medical (SILK) priced its initial public offering at 20 a share, at the high end of its recently raised expected range. The Silk Road IPO garnered lots of attention from investors, with one IPO research firm giving the company its highest rating. Silk Road stock will start trading Thursday.